Biotechnology Assets Sa Stock Cash And Equivalents
BST Stock | 0.34 0.01 3.03% |
Biotechnology Assets SA fundamentals help investors to digest information that contributes to Biotechnology Assets' financial success or failures. It also enables traders to predict the movement of Biotechnology Stock. The fundamental analysis module provides a way to measure Biotechnology Assets' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biotechnology Assets stock.
Biotechnology |
Biotechnology Assets SA Company Cash And Equivalents Analysis
Biotechnology Assets' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition |
In accordance with the recently published financial statements, Biotechnology Assets SA has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The cash and equivalents for all Spain stocks is 100.0% higher than that of the company.
Biotechnology Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biotechnology Assets' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biotechnology Assets could also be used in its relative valuation, which is a method of valuing Biotechnology Assets by comparing valuation metrics of similar companies.Biotechnology Assets is currently under evaluation in cash and equivalents category among its peers.
Biotechnology Fundamentals
Return On Equity | -0.74 | |||
Return On Asset | -0.0647 | |||
Profit Margin | (0.92) % | |||
Operating Margin | (0.63) % | |||
Shares Outstanding | 48.35 M | |||
Shares Owned By Insiders | 51.21 % | |||
Revenue | 3.28 M | |||
Gross Profit | 3.01 M | |||
EBITDA | (1.04 M) | |||
Book Value Per Share | 0.1 X | |||
Number Of Employees | 33 | |||
Beta | 1.51 | |||
Market Capitalization | 13.64 M | |||
Annual Yield | 0.53 % |
About Biotechnology Assets Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biotechnology Assets SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Assets using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Assets SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Stock
Biotechnology Assets financial ratios help investors to determine whether Biotechnology Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Assets security.